We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+39.07%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.38B
AUM Growth
+$198M
Cap. Flow
-$130M
Cap. Flow %
-5.45%
Top 10 Hldgs %
45.26%
Holding
80
New
15
Increased
16
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$84.7M
2
INSM icon
Insmed
INSM
+$82.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$61.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$50.7M
5
AUTL
Autolus Therapeutics
AUTL
+$37.9M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$98.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$80M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
4
KURA icon
Kura Oncology
KURA
+$43.5M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
76
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-2,000,000
Closed -$35.9M
TCDA
77
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-772,700
Closed -$8.1M
TCDA
78
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-1,177,680
Closed -$12.3M
FMTX
79
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-966,573
Closed -$19.3M
GBT
80
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-326,600
Closed -$22.2M
1 2 3
4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Deep Track Capital held 80 positions worth $2.38B, up 9.1% from $2.18B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Deep Track Capital withdrew a net $130M in Q4 2022, closing 20 positions and reducing 23 holdings. Its most notable exit was NovoCure, an estimated $98.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier.

Against the trend, Deep Track Capital opened a new position in Biogen worth $83.1M.

  • Deep Track Capital's largest Q4 2022 buy was Biogen: 300,000 shares worth $83.1M.
  • Deep Track Capital added most to DICE Therapeutics, Inc. Common Stock in Q4 2022, an estimated $23.9M increase.
  • Deep Track Capital's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $80M.
  • Deep Track Capital fully exited NovoCure in Q4 2022, selling an estimated $98.3M.
  • Deep Track Capital's ten largest holdings make up 45% of its $2.38B portfolio in Q4 2022.
  • Deep Track Capital opened 15 new positions and closed 20 in Q4 2022.
  • Deep Track Capital's portfolio value rose 9.1% quarter-over-quarter to $2.38B.

Based on Deep Track Capital's 13F filing for Q4 2022, filed 14 Feb 2023.